Vanda Pharmaceuticals (VNDA) Competitors $4.68 -0.04 (-0.85%) Closing price 04:00 PM EasternExtended Trading$4.72 +0.04 (+0.75%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VNDA vs. OPK, NVAX, GERN, RGLS, MYGN, ZBIO, EBS, LXRX, RIGL, and CBIOShould you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include OPKO Health (OPK), Novavax (NVAX), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), and Crescent Biopharma (CBIO). These companies are all part of the "biotechnology" industry. Vanda Pharmaceuticals vs. Its Competitors OPKO Health Novavax Geron Regulus Therapeutics Myriad Genetics Zenas BioPharma Emergent Biosolutions Lexicon Pharmaceuticals Rigel Pharmaceuticals Crescent Biopharma Vanda Pharmaceuticals (NASDAQ:VNDA) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability. Does the media prefer VNDA or OPK? In the previous week, OPKO Health had 3 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 4 mentions for OPKO Health and 1 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.93 beat OPKO Health's score of 0.52 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Vanda Pharmaceuticals Positive OPKO Health Positive Do institutionals & insiders believe in VNDA or OPK? 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 8.9% of Vanda Pharmaceuticals shares are owned by company insiders. Comparatively, 49.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher earnings and valuation, VNDA or OPK? Vanda Pharmaceuticals has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVanda Pharmaceuticals$198.77M1.39-$18.90M-$0.75-6.24OPKO Health$713.10M1.48-$53.22M-$0.07-19.00 Which has more risk and volatility, VNDA or OPK? Vanda Pharmaceuticals has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Do analysts recommend VNDA or OPK? Vanda Pharmaceuticals currently has a consensus price target of $16.50, indicating a potential upside of 252.56%. OPKO Health has a consensus price target of $2.75, indicating a potential upside of 106.77%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Vanda Pharmaceuticals is more favorable than OPKO Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50OPKO Health 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is VNDA or OPK more profitable? OPKO Health has a net margin of -5.66% compared to Vanda Pharmaceuticals' net margin of -21.98%. OPKO Health's return on equity of -2.85% beat Vanda Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vanda Pharmaceuticals-21.98% -8.30% -6.85% OPKO Health -5.66%-2.85%-1.82% SummaryOPKO Health beats Vanda Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNDA vs. The Competition Export to ExcelMetricVanda PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$278.17M$2.85B$5.48B$8.94BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-6.2421.1726.2519.74Price / Sales1.39262.85405.80109.12Price / CashN/A41.8936.4957.06Price / Book0.517.237.925.37Net Income-$18.90M-$55.05M$3.15B$248.34M7 Day Performance4.00%-0.74%0.95%1.25%1 Month Performance6.61%6.27%5.25%5.41%1 Year Performance-16.13%0.19%32.63%18.06% Vanda Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNDAVanda Pharmaceuticals4.6204 of 5 stars$4.68-0.8%$16.50+252.6%-16.5%$278.17M$198.77M-6.24290OPKOPKO Health4.4474 of 5 stars$1.32flat$2.75+108.3%+5.6%$1.05B$713.10M-18.852,997NVAXNovavax4.5045 of 5 stars$6.30-1.1%$17.00+169.8%-50.2%$1.02B$682.16M2.381,990GERNGeron3.2601 of 5 stars$1.41-5.4%$5.06+259.0%-66.7%$898.06M$76.99M-6.7170RGLSRegulus Therapeutics2.199 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830MYGNMyriad Genetics4.4531 of 5 stars$5.31+1.1%$14.38+170.9%-78.3%$489.48M$837.60M-4.742,700ZBIOZenas BioPharma1.7785 of 5 stars$9.69+1.1%$36.67+278.4%N/A$405.37M$15M-2.73N/AEBSEmergent Biosolutions4.1914 of 5 stars$6.38+0.5%$14.33+124.7%-6.5%$346.31M$1.04B-2.352,420Gap DownLXRXLexicon Pharmaceuticals2.4085 of 5 stars$0.95+15.2%$3.67+287.7%-43.7%$341.86M$31.08M-1.85140Gap DownRIGLRigel Pharmaceuticals2.8291 of 5 stars$18.73-3.9%$36.40+94.3%+127.9%$334.71M$179.28M9.05160CBIOCrescent Biopharma3.2451 of 5 stars$16.14+1.5%$25.00+54.9%N/A$315.54M$10K-0.3526High Trading Volume Related Companies and Tools Related Companies OPKO Health Competitors Novavax Competitors Geron Competitors Regulus Therapeutics Competitors Myriad Genetics Competitors Zenas BioPharma Competitors Emergent Biosolutions Competitors Lexicon Pharmaceuticals Competitors Rigel Pharmaceuticals Competitors Crescent Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VNDA) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
